13 May 2026
13 May 2026
The CE mark was granted based on data from retrospective studies in real-world early cognitive decline population.
During the open-label dose titration and stable dose periods, all participants received Lumryz, showing improved ESS scores.
The proceeds will be used to accelerate Isomorphic Labs’ pipeline of therapeutic programmes and further develop its IsoDDE AI drug design engine.
The study will enrol around 50 high-risk coronary artery disease patients whose resting ECGs show no signs of ischemia.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
